195.24 -0.23 (-0.12%)
Pre-Market: 8:12AM EDT
|Bid||190.61 x 900|
|Ask||195.21 x 800|
|Day's Range||194.33 - 196.66|
|52 Week Range||166.30 - 211.90|
|Beta (3Y Monthly)||0.80|
|PE Ratio (TTM)||15.52|
|Forward Dividend & Yield||5.80 (2.99%)|
|1y Target Est||N/A|
Shares of Amgen are on an upswing after winning a patent battle over its drug Enbrel against Novartis subsidiary Sandoz. Is it time to buy shares of the massive biotech company?
Jaclyn Schuler’s role as a leader at Amgen in Tampa is to motivate her teams to deliver value and impact the bottom line.
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
Shares of pharmaceutical companies toppled Tuesday on reports the House of Representatives will release a plan that allows the federal government to negotiate drug prices in Medicare.
Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Amgen stock toppled Monday after the biotech company's experimental cancer treatment failed to impress investors in a Phase 1 study. The drug attempts to inhibit a protein known as KRAS.
Microsoft Corp and Amgen Inc were among the biggest drags on the S&P 500 and Nasdaq. Amgen fell 3.19% after analysts raised questions about data on the company's lung cancer drug, dragging the healthcare sector down 0.94%. Financial stocks rose 1.20%, providing the biggest boost to the S&P 500, with banks gaining 2.62%.
Amgen said in a Sunday statement that new data from the Phase 1 study of AMG 510 presented as an oral presentation at the IASLC 2019 World Conference on Lung Cancer, or WCLC, showed that out of the 13 of the evaluable patients receiving the target dose of 960mg once daily — the highest dose — seven, or 54%, achieved a partial response at one or more timepoints and six achieved stable disease. Nine of the 13 patients are continuing to take the daily pill, Amgen said. Of the partial responders, two died and another quit the study due to disease progression.
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
New data on a key drug in Amgen’s cancer pipeline sent shares of the company down 3.6% in premarket trading on Monday, though the company said it remained enthusiastic about the promise of the drug.
Yahoo Finance's Dan Roberts, Sibile Marcellus, and Julia La Roche discuss Amgen's falling stock after it's key lung cancer drug missed Wall Street forecasts.
Nissan CEO, Hiroto Saikawa, is stepping down September 15th after a controversial term. Meanwhile, Elliot Management takes a $3.2B stake in AT&T, Amgen's drug trial came in short of Wall Street expectations and Amazon is set to hold a nationwide career day on September 17th. Yahoo Finance's Ines Ferre breaks down the details from the New York Stock Exchange.